Posted by Michael Wonder on 23 Oct 2024
FDA approves NGS based companion diagnostic for first targeted therapy for patients with grade 2 IDH mutant glioma
21 October 2024 - Oncomine Dx target test to identify patients eligible for Servier’s Voranigo (vorasidenib) tablet, the only FDA approved treatment for grade 2 IDH mutant glioma.
Thermo Fisher has received approval from the US FDA for its Ion Torrent Oncomine Dx target test as a companion diagnostic to identify patients eligible for treatment with Servier's Voranigo (vorasidenib) tablets.
